FIGO and IMS Reframe Hormone Therapy for Premature Ovarian Insufficiency

This joint FIGO-IMS position paper reconceptualizes POI and early menopause as chronic endocrine conditions requiring higher-dose, longer-duration hormone replacement rather than symptom-driven menopause management.

FIGO-IMS joint position paperInternational Federation of Gynecology and ObstetricsInternational Menopause Societypremature ovarian insufficiencyearly menopausehormone therapyestradiolprogestogensNK3R antagonists Women's Health

Background Information

Time to rethink hormone therapy for early menopause.

Premature ovarian insufficiency (POI) and early menopause (EM) lead to longer estrogen deficiency, increasing risks of various health issues. The paper advocates for a shift in managing POI/EM as chronic endocrine conditions, emphasizing timely hormone therapy (HT) initiation and long-term care. This position paper suggests reframing HT as essential preventive care for POI/EM, highlighting the need for awareness and equitable access to multidisciplinary care. POI and EM require proactive hormonal management to prevent long-term health issues.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Benedetto C, Khadilkar SS, Nappi RE, Genazzani AR, Frezet F, Cucinella L, Divakar H, Anagnostis P, Panay N

Citation: Benedetto C, Khadilkar SS, Nappi RE, et al. Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper. Climacteric : the journal of the International Menopause Society. 2026;29(4):487-506. doi:10.1080/13697137.2026.2691828

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →